Acrivon Therapeutics said the Food and Drug Administration has granted Breakthrough Device designation for its ... care providers with timely access to medical devices by speeding up development ...

The ACR-368-tailored OncoSignature assay is being used to predict patients most likely to respond to ACR-368 in Acrivon’s ongoing, ...

The US Food and Drug Administration (FDA) has granted breakthrough device designation to CergenX ... expedite the route to market for innovative medical devices. CergenX’s technology uses ...

“We are honored to be awarded Breakthrough Device Designation for our Serial CTRS ... s platform is applied at the point of care to medical oncologists and is also leveraged by global ...

The FDA’s Breakthrough Device Designation is reserved for medical devices that offer significant advantages over existing standards of care, addressing unmet medical needs or providing critical ...

(RTTNews) - Acrivon Therapeutics, Inc. (ACRV), Wednesday, announced that the FDA has granted Breakthrough Device designation for the ACR-368 OncoSignature assay for the treatment of endometrial ...

The FDA’s Breakthrough Device Designation is reserved for medical devices that offer significant advantages over existing standards of care, addressing unmet medical needs or providing critical ...